Abivax says FDA pre-NDA talks support obefazimod ulcerative colitis filing plan
ABVX•FDA pre-NDA interaction supports filing plan
Abivax says it secured FDA alignment in a pre-NDA interaction for obefazimod in moderately to severely active ulcerative colitis.
The company kept its target to file its first U.S. New Drug Application by end-2026.
